Fingolimod Administered Orally Once Daily vs Interferon Beta-1a i.m. Once Weekly in Pediatric Patients with Multiple Sclerosis

-
Investigator: Emmanuelle L. Waubant, MD, PhD
Sponsor: Novartis Pharma AG

Location(s): United States

Description

PARADIGMS is a 24-month research study intended to see if an FDA-approved oral disease modifying treatment (DMT) for adult patients can help children with MS.